Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules
Platform Designed For More Precisely Targeted Drugs
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
You may also be interested in...
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Keeping Track: US FDA Acts On 5 Novel Drugs: Approval For Fotivda, Pepaxto, Azstarys; CRLs For Defencath and Oral Paclitaxel
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.